Annovis Bio Statistics
Total Valuation
Annovis Bio has a market cap or net worth of $65.30 million. The enterprise value is $59.54 million.
| Market Cap | 65.30M |
| Enterprise Value | 59.54M |
Important Dates
The next estimated earnings date is Tuesday, May 21, 2024, before market open.
| Earnings Date | May 21, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Annovis Bio has 11.01 million shares outstanding. The number of shares has increased by 10.55% in one year.
| Shares Outstanding | 11.01M |
| Shares Change (YoY) | +10.55% |
| Shares Change (QoQ) | +10.13% |
| Owned by Insiders (%) | 24.59% |
| Owned by Institutions (%) | 11.95% |
| Float | 8.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.39
| Current Ratio | 2.39 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -565.10%.
| Return on Equity (ROE) | -565.10% |
| Return on Assets (ROA) | -326.80% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$9.37M |
| Employee Count | 6 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -60.36% in the last 52 weeks. The beta is 1.76, so Annovis Bio's price volatility has been higher than the market average.
| Beta (1Y) | 1.76 |
| 52-Week Price Change | -60.36% |
| 50-Day Moving Average | 9.80 |
| 200-Day Moving Average | 10.31 |
| Relative Strength Index (RSI) | 40.73 |
| Average Volume (30 Days) | 493,703 |
Short Selling Information
The latest short interest is 1.45 million, so 13.19% of the outstanding shares have been sold short.
| Short Interest | 1.45M |
| Short Previous Month | 1.35M |
| Short % of Shares Out | 13.19% |
| Short % of Float | 17.84% |
| Short Ratio (days to cover) | 5.12 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -45.04M |
| Pretax Income | -56.20M |
| Net Income | -56.20M |
| EBITDA | -56.20M |
| EBIT | -56.20M |
| Earnings Per Share (EPS) | -$6.23 |
Balance Sheet
The company has $5.75 million in cash and no debt, giving a net cash position of $5.75 million or $0.52 per share.
| Cash & Cash Equivalents | 5.75M |
| Total Debt | n/a |
| Net Cash | 5.75M |
| Net Cash Per Share | $0.52 |
| Equity / Book Value | -7.75M |
| Book Value Per Share | -0.70 |
| Working Capital | 5.93M |
Cash Flow
| Operating Cash Flow | -39.97M |
| Capital Expenditures | n/a |
| Free Cash Flow | -39.97M |
| FCF Per Share | -$4.43 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Annovis Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.55% |
| Shareholder Yield | -10.55% |
| Earnings Yield | -86.07% |
| FCF Yield | -61.21% |
Analyst Forecast
The average price target for Annovis Bio is $17.50, which is 195.11% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $17.50 |
| Price Target Difference | 195.11% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |